# Everest Organic (NSE: EVERESTO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/EVERESTO · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹262 Cr, it ranks 2122nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −1.8% in FY25. Promoters held 59.60% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹262 Cr |
| ROE | −1.8% (FY25) |
| ROCE | 2.3% (FY25) |
| Debt to equity | 0.68 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹159 Cr | −₹1 Cr |
| FY24 | ₹197 Cr | ₹0 Cr |
| FY23 | ₹183 Cr | −₹0 Cr |
| FY22 | ₹200 Cr | ₹1 Cr |
| FY21 | ₹182 Cr | ₹14 Cr |
| FY20 | ₹167 Cr | ₹11 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 59.60%
- Domestic institutions: 0.02%
- Non-institutions: 40.37%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |
| [Gennex Labs](https://app.pivotnow.in/stock/GENNEX) | — | ₹254 Cr | — | — |
| [Kerala Ayur](https://app.pivotnow.in/stock/KERALAYUR) | — | ₹254 Cr | — | — |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹132.60 | ₹252 Cr | 6.3 | — |
| [BDH Industries](https://app.pivotnow.in/stock/BDH) | — | ₹252 Cr | — | — |

## Questions and answers

### What is the market cap of Everest Organic?

Everest Organic's market capitalisation is ₹262 Cr (₹262 Cr) at the 22 Oct 2026 close, ranking 2122nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Everest Organic?

Return on equity was −1.8% in FY25 and return on capital employed was 2.3% in FY25 (standalone figures).

### Is Everest Organic a debt-free company?

No. Everest Organic's debt-to-equity ratio was 0.68 in FY25, with total debt of ₹9 Cr.

### What is the shareholding pattern of Everest Organic?

As of 30 Jun 2026: promoters 59.60%, domestic institutions 0.02%, non-institutions 40.37%.

### Who are Everest Organic's competitors?

The listed Pharma & Healthcare companies closest to Everest Organic by market cap are Espire Hospital, Zenotech Labs, Gennex Labs, Kerala Ayur, Nath Bio-Genes (India) and BDH Industries.

### Is Everest Organic a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Everest Organic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EVERESTO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.